SOURCE: Cavit Sciences, Inc.

January 30, 2008 08:00 ET

Cavit Sciences, Inc. Completes Relocation and Expansion

MIAMI, FL--(Marketwire - January 30, 2008) - Cavit Sciences, Inc. ("Cavit") (OTCBB: CVIT) announced today that it has completed the relocation and occupancy of its corporate headquarters to a research and technology complex in North Miami, Florida. The Company has developed two unique supplement lines and is developing treatments for diseases. The new Cavit facility is significantly larger than the Company's previous space and accommodates our research and development, operations and marketing. The space has been designed to meet Cavit's unique requirements for two separate facilities; one for the development of the supplement lines and the second for the development of cancer and viral infection treatments. The facility includes research labs, clinical testing labs, clean rooms, development labs, corporate offices and warehouse space.

Colm King, Cavit's CEO, commented, "The Company is experiencing the planned growth of our business strategy. Cavit's space needs have grown with the development of our supplement lines and the ongoing development of treatments for diseases. As we continue to grow, our new facilities will allow us to develop and commercialize additional products."

Cavit's New Address:
20 NW 181st Street
Miami, FL 33169
Tel: 305-493-3304
Fax: 305-493-3308

Cavit Sciences, Inc. ("Cavit") is a biotechnology company that has developed two supplement lines with products that enhance, improve, maintain and support the body by beneficially effecting various conditions and is engaged in developing treatments and prevention for cancer, viral infections, opportunistic infections, related diseases and the immune system. Product information and updates will soon be available on Cavit's website. Additional information regarding our supplement lines, treatment development and Company information is available on the Company's website at:

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cavit. These factors include, but are not limited to: (i) the ability of Cavit to successfully raise financing, (ii) the ability of Cavit to finalize its manufacturing and distribution facilities, and (iii) the ability of Cavit to successfully commercialize its products in certain markets. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cavit's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" for Cavit on Form 10K-SB filed on April 12, 2007 and its subsequently filed Forms 10-QSB.

Contact Information